Helicobacter pylori infection
Conditions
Interventions
Experimental group 1:high-dose Vonoprazan-tetracycline dual
Experimental group 2:low-dose Vonoprazan-tetracycline dual
Sponsors
The First Affiliated Hospital, Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1: participants aged 18–70 2: no history of of receiving H. pylori eradication therapy 3: confirmed H. pylori infection by at least one of the following tests: urea breath test, histology exam and positive bacterial culture 4: history of allergic to penicillin or positive in penicillin allergy skin test
Exclusion criteria
Exclusion criteria: 1: used antibiotics,bismuth,or acid inhibitor use, including H2 receptor antagonist, PPI or P-CAB within four weeks before inclusion 2: current pregnancy or breastfeeding 3: allergy to any of the study drugs 4: history of gastrectomy 5: gastric malignancy 6: Gastroduodenal ulcer with recent hemorrhage or signs of hemorrhage within 4 weeks 7: preexisting serious diseases or clinical conditions that might interfere with the evaluation of study treatment, including patients with active central nervous system disorders and hematological disorders, hepatic or renal dysfunction, heart disorders, etc. 8: difficulty with oral feeding or receiving parenteral nutrition support 9: administration of ampicillin, amoxicillin, estradiol, diethylstilbestrol, glibenclamide, glipizide, glimepiride, potassium citrate, progesterone, toluenesulfonylurea, magnesium sulfate, magnesium aluminum carbonate, aluminum hydroxide, calcium lactate, atazanavir, nelfinavir, or rilpivirine, erlotinib, gefitinib, pembrolizumab, ceritinib, or soridjib, midazolam, digoxin, voriconazole, clopidogrel, isotretinoin, avicularin, retinol, bexarotene, barbiturates, sodium phenytoin, carbamazepine, anticoagulants, mezlibenzone, tegafur, methotrexate, or rifampin during the trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Eradication rates of Helicobacter pylori; | — |
Secondary
| Measure | Time frame |
|---|---|
| adverse events;compliance; | — |
Countries
China
Contacts
Public ContactTianlian Yan
The First Affiliated Hospital, Zhejiang University School of Medicine
Outcome results
None listed